This new software is compatible with both Windows and macOS operating systems, making it a generic solution for users of different platforms.
这款新软件与Windows和macOS操作系统都兼容，使其成为不同平台用户的通用解决方案。
The pharmacy carries a range of generic medicines that are just as effective but cost less than their branded counterparts.
药房备有一系列仿制药，它们与品牌药一样有效但价格更低。
It's important to establish generic programming skills since they are applicable across various coding languages.
掌握通用编程技能很重要，因为这些技能可以应用于多种编程语言中。
The company offers generic training sessions that cover basic customer service skills applicable to any industry.
该公司提供涵盖适用于任何行业的基本客户服务技能的通用培训课程。
A generic error message doesn't specify the exact problem, making troubleshooting more challenging.
通用错误信息没有明确指出具体问题，使得故障排除更加困难。
The design of this furniture is quite generic, fitting into multiple interior styles without standing out too much.
这款家具的设计相当通用，能融入多种室内风格而不显得过于突出。
Generic terms in a contract allow for flexibility in interpretation and application across different situations.
合同中的通用条款允许在不同情况下进行灵活解释和应用。
The new app features a generic login system that accepts credentials from various social media platforms.
新应用程序具有一项通用登录系统，可接受来自多个社交媒体平台的凭据。
In programming, using generic functions allows you to work with different data types without writing separate code for each one.
在编程中，使用泛型函数可以让你在不为每种类型编写单独代码的情况下处理不同数据类型。
The study analyzed the impact of generic advertising on consumer behavior across multiple product categories.
该研究分析了通用广告对多个产品类别消费者行为的影响。
The Geneva-based Medicines Patent Pool's offer of a non-exclusive sublicense to several Chinese enterprises to produce the generic version of Pfizer's oral COVID-19 treatment can help mitigate poor access to COVID-19 medicines, industry experts and business leaders said on Friday, adding the offer is also a recognition of the Chinese makers' capability to produce high-quality drugs.
行业专家和商界领袖周五表示，基于基因的药物专利库向几家中国企业提供非排他性转授许可，以生产辉瑞口服新冠肺炎的仿制药，这有助于缓解新冠肺炎药物的获取困难，并补充说，这一提议也是对中国制造商生产高质量药物能力的认可。
According to Liu Jubo, CEO of Chinese biologics company Evive Biotech, the nation's pharmaceutical industry has been shifting from mainly producing generics to innovation-driven novel drug development, and strong independent R&D capability will be the core competence of companies seeking to achieve sustainable growth or expand their global footprint.
据中国生物制药公司Evive Biotech的首席执行官刘巨波表示，中国的制药行业正在从主要生产仿制药转向以创新驱动的新药研发，而强大的独立研发能力将是寻求实现可持续增长或扩大全球影响力的企业核心竞争力。
Teva Pharmaceuticals, the world's largest generic medicine company, is training sights on China as one of its 'most relevant growth engines" in the coming years, according to the company's senior executives.
In China, Teva adopts a clear "3-3-3" strategy, meaning a focus on three therapeutically areas, namely central nervous system, respiratory conditions and oncology; three portfolio segments that range from innovative, complex generics and selective generics, as well as three big cities-Beijing, Shanghai and Guangzhou-for early-phase penetration in the country.
BeiGene President Wu Xiaobin said the green light also underlines China's progress in upgrading its pharmaceutical sector from its traditional strategy of making generic drugs to innovation-driven drug development.
Qingdao Baheal Pharmaceutical Co Ltd, a holding subsidiary of Chinese pharmaceutical giant Baheal Pharmaceutical Group, announced on Tuesday that its high-end generic medicine, "Nida", an extended-release tablet containing metformin for type-2 diabetes management, was officially launched in China.
中国医药巨头百汇医药集团的控股子公司——青岛百汇海德医药有限公司于周二宣布，其高端仿制药“尼达”（Nida）正式在中国上市。该药品是一种含有二甲双胍的长效缓释片，用于治疗2型糖尿病。
Chinese authorities reviewed the generic under fast track and approved its market launch in January.
"He explained that in the US, a typical mature pharmaceutical market, about 70 percent of the medicine expenditure paid by medical insurance are for original, innovative, or rare drugs, while in China about 80 percent of the payments from the public medical insurance funds are on generics, causing great financial burden to both patients and society.
That drives the authorities to reform related regulations and mechanisms to restructure the domestic market, with a focus on development and procurement of high-quality generics and novel drugs, which is creating room for further cooperation between domestic and foreign companies to explore new opportunities on R&D and marketing of high-quality generics and new drugs, he said.
The policy brought in new concepts and practices to the academic, clinical and business communities, and helped ignite pharmaceutical innovation and boosted generic drug quality in China.
"China's medicine reforms in recent years are driving Chinese companies to focus more on new drug R&D and innovation to optimize product portfolios toward medium-to-high end returns, instead of simply profiting from the production and sales of low-quality generics, he said.
Deeper discounts on generic products stoke group-buying, boost e-shoppingWu Weidong was never much of an online shopper.
But the success of Pinduoduo's model, which offers users deeper discounts on mostly generic products if they buy in groups, and encourages them to share purchases through messaging app WeChat, is driving Alibaba and JD to make a fresh push into China's lower-tier cities.
So whenever a generic medicine comes in after our patent expires, our sales in that particular drug decline.
"Even though the market space for developing generic drug is fairly attractive, we will continue to focus on developing innovative drugs, because we are inspired by the progress China has been making to give more easy access for the patients to both home-made and imported drugs," said Du.
It cited the example of Sealuxe and iLife, two homegrown brands that are working closely with online influencers through generic brand promotion campaigns and new product launches.
According to Zhao, the company has filed nine new generic drug applications - known as abbreviated new drug applications or ANDAs - to the US Food and Drug Administration, and five have been approved.
The market size of approved generics is huge, making it less difficult to tap the US market, he added.
The company plans to export high-quality generics to the US, as well as expand its business in the European market once it gets more ANDAs approved in the US.
"Over the last 20 years China has been able to evolve from a country that was primarily focused on generic medicines and vaccines to now being able to bring the latest innovations," he said.
Qingdao Baheal Pharmaceutical Co Ltd, a holding subsidiary of Chinese pharmaceutical giant Baheal Pharmaceutical Group, announced on Tuesday that the first batch of advanced generic medicine the company has developed for type-2 diabetes will soon be delivered to the United States market.
The generic medicine, called "Nida", is an extended-release tablet containing metformin, a chemical widely used in type-2 diabetes management.
The original drug is a best-seller drug for diabetes in the US, and Qingdao Baheal Pharmaceutical's generic medicine received approval from the US Food and Drug Administration's under review of generic drug applications, known as abbreviated new drug applications, in late 2018.
The Chinese drug regulator is reviewing the generic under fast track, as the drug has been approved in the US, and will hopefully approved for Chinese market in near future, the company said.
In recent years, an increasing number of Chinese pharmaceuticals have filed abbreviated new drug applications to the US authorities for their generics, because the eye the huge US market, but also because Chinese authorities encourage the development of high-quality generics, and would adopt fast-track review for generics that are made in China and have received US approvals, according to Lei Jifeng, company board member of the company.
They don’t want the same, generic, institutionalized hotels all over the world.
On the one side, with the generic companies, the quality of their products was not always the best, but now their quality is becoming better generally.
So, competition with generic products is going to be tougher, and there will be more pressure on price.
""Coking coal is fairly generic and very common around the globe but the metallurgical coal is where they are getting their margins up.
"The new reactor design from China, the UK HPR1000, developed by CGN and China National Nuclear Corporation is undergoing a phase-two process in the Generic Design Assessment in Britain, which allows regulators to begin assessing the safety, security and environmental aspects of new reactor designs.
Gavin Edwards, Hualong generic design assessment officer at General Nuclear System, said his team takes a long-term view in bringing HPR1000 technology to the UK.
Gavin Edwards, Hualong generic design assessment officer at General Nuclear System, said his team takes a longterm view in taking HPR1000 technology to the UK.
If HPR1000 passes the UK's very strict assessment process, Generic Design Assessment, CGN plans to use the technology for the construction of the UK's Bradwell B nuclear power station.
Shanghai-based Fosun Pharmaceutical Group will downsize its planned acquisition stake in the Indian generic drugmaker Gland Pharma to 74 percent from the previously announced 86 percent, according to a Fosun Pharmaceutical announcement released on Monday.
Chen Qiyu, chairman of Fosun Pharmaceutical, said that the integrated resources of Chinese and Indian pharmaceutical companies, such as Fosun Pharmaceutical's acquisition of Gland Pharma, will help promote the internationalization of Chinese pharmaceutical companies in research and development and generic drug export.
Headquartered in Hyderabad, India, Gland Pharma is a leading Indian pure-play generic injectable pharmaceutical products company founded 39 years ago.
If HPR1000 passes the UK’s very strict assessment process, Generic Design Assessment, CGN plans to use the technology for the construction of the UK's Bradwell B nuclear power station.
Shanghai Fosun Pharmaceutical Group announced on Monday it will acquire an approximately 74 percent stake in the Indian generic drug maker Gland Pharma, down from the 86 percent stake announced last July.
Headquartered in Gland Hyderabad, India, Pharma is a leading Indian pure play generic injectable pharmaceutical products company founded 39 years ago.
Gland Pharma, as one of the world's largest providers of injectable generic medicines, is India's first injectable drugs manufacturer to be approved by the US FDA.
The resource grafting of Chinese and Indian pharmaceutical companies represented by Fosun Pharma and Gland Pharma will help promote the internationalization of Chinese pharmaceutical companies in R&D innovation and generic drug export," Chen Qiyu, co-president of Fosun Group and chairman of Fosun Pharmaceutical, said in the announcement.
"We finished the first stage of the four stages in Generic Design Assessment (GDA) and we are about to start the second," he said.
In March, both companies expressed a willingness to acquire German generic and over-the-counter drugs maker Stada Arzneimittel.
Gland Pharma, based in the southern Indian city of Hyderabad, is one of world's largest providers of injectable generic medicines.
The deal could be Germany's second largest by a private equity firm if buyout groups Bain Capital and CinvenStada succeed in buying generic drugmaker Stada.
The companies will seek to get the Hualong One technology approved in the UK via an assessment known as the Generic Design Assessment process.
"The UK government asked nuclear regulators to begin the Generic Design Assessment of CGN's Hualong One reactor design, China's domestically developed third-generation reactor, in January, a process that industry experts expect to take about 60 months in four phases.
CEEC is a generic term that refers to Central and Eastern European Countries.
"Chinese e-commerce platforms, real estate, education, generic drugs and vaping were the sectors hardest hit by the recent COVID-19 outbreak across the country," Hoogewerf said.
The research and development of industrial generic technology will be supported.
Meanwhile, the nation will further develop industrial internet and build additional platforms for generic technology research and development to enhance the capacity of MSMEs to make innovations and engage in specialized production.
The company owns multiple branded generic medicines in the field of women's health, all aimed at making quality medicines more accessible to more women.
Data from the Center for Drug Evaluation under the National Medical Products Administration showed that in November, 118 innovative drugs developed by domestic companies were registered, while the figure for generic drugs was 183.
Generic drugs, traditional Chinese medicine, or TCM, auxiliary drugs and imported drugs still dominate, while innovative drugs take up a small proportion of the overall market, industry experts said.
Li Xinchuang, chief engineer of Beijing-based China Metallurgical Industry Planning and Research Institute, said to develop low-carbon generic technologies for the steel sector and explore decarbonization solutions is a positive move to cooperate and promote low-carbon technological innovation.
Those changes include lower market tolerance for low-end generics, faster new drug review and registration processes, a stronger play of market mechanisms and fiercer domestic market competition even among innovative drugs.
"China's medicine reforms in recent years have been pushing Chinese companies to increase investments in new drug R&D and innovation to enhance product portfolios, instead of simply profiting from the production and sales of low-quality generics," said Shi Lichen, founder of medical consultancy Beijing Dingchen Consultancy.
Merely a few years ago, domestic enterprises tended to produce low-end generics that could generate near-term returns, instead of innovative or original drugs that need large R&D investments and face uncertainties in achieving success in the marketplace.
Those measures include the generic consistency evaluation program, which reviews the quality and efficacy of the generic drugs as compared to the corresponding brand-name versions, the reforms of clinical trial and new drug review procedures to speed up the related process, and the volume-based procurement program that lowers drug prices and urges companies to innovate and strengthen their R&D.
Stressing the importance of innovation, the guideline called for enhanced investment in research and development from major enterprises and breakthroughs in more than 20 key generic technologies.
The reactor has met the standard of the Generic Design Assessment, according to a joint statement issued on Monday by the British Office for Nuclear Regulation and the Environment Agency.
"A decade ago, the most common practice in the domestic biopharma field was to produce generic drugs, and therefore most drugs were for the treatment of diseases with a high incidence in the West－but not necessarily high in China," Wang said.
Generic or inferior organizations will struggle to attract and retain customers and good employees.
“普通或低劣的组织将难以吸引并留住客户及优秀员工。”
Since investing in new drug development does not produce instant or even near-term returns and hence is regarded as risky, domestic pharmaceutical companies tended to produce low-end generics, preferring not to develop innovative or original drugs even when there was high demand.
由于投资新药开发不会立即或近期产生回报，因此被视为风险投资，国内制药公司往往倾向于生产低端仿制药，即使在需求量大的情况下也不愿开发创新或原创药物。
There were thousands of such small or medium-sized firms that focused on generics, active pharmaceutical ingredients and traditional Chinese medicine.
有成千上万的这种中小型企业专注于仿制药、活性药物成分和传统中药。
Over the years, regulators focused on measures that encourage innovation, especially research and development of new drugs in line with global developments, or as per urgent clinical demand, and also to speed up clinical trial registration and new drug reviews, in order to enhance domestic generics and help bring down drug prices.
多年以来，监管机构一直专注于鼓励创新的措施，特别是与全球发展同步或根据临床紧急需求研发新药，并加快临床试验注册和新药审查，以增强国内仿制药，并帮助降低药品价格。
With the domestic market exerting the pressure of demand for high-quality products, local pharmaceutical companies now invest more in innovation and R&D to make high-end generics and innovative drugs.
由于国内市场对高质量产品的需求压力，国内制药公司现在在创新和研发方面投入更多资金，以生产高端仿制药和创新药物。
Official data showed there were three rounds of volume-based drug procedure programs so far, which helped cut the average price of 112 drugs by generic name by 54 percent, saving 53.9 billion yuan ($8.2 billion) in medical costs for patients.
官方数据显示，到目前为止，已经进行了三轮基于药品成交量的采购项目，这使得112种通用名药物的平均价格降低了54%，为患者节省了539亿元（约合82亿美元）的医疗费用。
Intensifying competition in China's pharmaceutical industry has led to a long-awaited transformation in which more companies have now upgraded and continuously improve their capabilities in developing generics that are better formulated with better delivery systems, while others reinvent themselves as better innovators, said a senior industry expert.
一位资深行业专家表示，中国制药行业竞争加剧，期待已久的变革已经开始。现在，更多的公司已经升级，并不断改进其开发具有更好配方和递送系统的仿制药的能力，而其他公司则重塑自我，成为更好的创新者。
Starting in 2015, China began rolling out a series of documents, regulations and programs in the medical products sector, including reforms in the new drug review and approval system, the generic drug quality and efficacy consistency evaluation and the volume-based tendering policy to shorten the clinical trial process, speed up new drug registrations and encourage innovation.
自2015年起，中国开始在医药产品领域推出一系列文件、法规和项目，包括新药评审审批制度改革、仿制药质量和疗效一致性评价以及量价挂钩招标政策等，以缩短临床试验过程、加快新药注册和鼓励创新。
In 2019, fixed-asset investment in the domestic pharmaceutical industry-mostly in new drug R&D, generic drug quality and efficacy consistency evaluation and registration in overseas markets-increased 8.4 percent from a year earlier, up 4.4 percentage points from 2018, Wang said.
王总表示：“2019年，国内医药行业固定资产投资——主要集中在新药研发、仿制药质量和疗效一致性评价以及海外市场的注册——比上年同期增长8.4%，比2018年高出4.4个百分点。”
Among those treatments, six either cost less than 100,000 yuan ($14,953) a year or have cheaper versions of generics, and five have especially good efficacy for five rare diseases, which cost more than 1 million yuan a year and require life-long medication.
在这些治疗方案中，有六种每年的费用低于10万元人民币（约合14,953美元），或者有更便宜的仿制药版本，还有五种对五种罕见病有特别好的疗效，这些病每年的治疗费用超过100万元人民币，并且需要终生服药。
Favorable policies spur transformation as profit margins for generic drugs shrinkPharmaceutical enterprises from home and abroad are stepping up efforts in innovative drug research and development as the domestic innovation environment constantly improves and profit margins for generic drugs gradually shrink, said industry experts.
"With favorable policies for innovative drugs and reducing profits for generic drugs, innovation has become the only way for the development of high-quality pharmaceutical enterprises," Zhang said.
One supportive policy behind this is the centralized generic drug procurement policy, which effectively lowered generic drug prices and decreased their profit margins.
China also seeks to achieve more breakthroughs in key generic technologies.
In 2019, the United States Food and Drug Administration approved or tentatively approved 86 new generic drug applications－known as abbreviated new drug applications or ANDAs－from Chinese pharmaceutical firms, according to a recent report from the China Chamber of Commerce for Import and Export of Medicines and Health Products.
Among the approvals, three were for first generic drugs, which allow holders a 180-day marketing exclusivity period.
The Healthcare Executive Institute, a Beijing-based think tank, also showed an upward trend in the number of generic drug approvals Chinese companies have received from the FDA in recent years.
In 2018, Chinese drugmakers received 79 generic drug approvals.
In 2019, Chinese companies conducted overseas M&As in areas including blood products, generic drugs, medical devices, contract development and manufacturing organizations (CDMOs), contract research organizations (CROs), biomedicine as well as nutrition and healthcare, the chamber said.
"China's traditional drug research and development pattern, which was dominated by generic drugs, is undergoing transformation, and new drug development has ushered in new opportunities.
He commented that due to changes in regulatory and market environment, including faster new drug registration process, lower market tolerance for low-end generics, and fierce competition to get onto hospital purchase lists, Chinese pharmaceutical companies have had to build up innovation and R&D capabilities to increase competence.
However, a selected drug, if a generic, must pass the consistency evaluation on quality and effectiveness against its original drug.
"Most Chinese companies start with generics as a market follower, and now many are trying to flip their product portfolios for more innovative drugs with increased efforts," she said.
"Chinese companies used to focus on generics, but now they have been building up R&D capabilities and many invest generously in innovative drugs.
Chen Qiulin, deputy director of the Health Industry Development Research Center at the Chinese Academy of Social Sciences, observed Chinese pharmaceutical companies now pay increasing attention to innovation and R&D, because the domestic pharmaceutical market has been changing focus to high-quality and cost-effective drugs, instead of low-end and cheap generics, and innovation brings about better returns in the long term.
Wang said the measures the Chinese government has adopted to increase the affordability and accessibility of medicine, such as the pilot drug group-buying program and the generic drug evaluation method, have intensified competition among pharmaceutical companies, which eventually helps cut prices.
"China has huge market potential for imported medicine, and the demand is growing fast for generic drugs, but pharmaceutical market competition is becoming increasingly fierce," he said.
Shi said competition in the generic drugs segment will be intense, considering the reimbursement provided by medical insurance programs in China for generic drugs is much more generous than in other countries, such as the US.
Shi Lichen, founder of medical consultancy Beijing Dingchen Consultancy, said more formulations, mostly generic medicines, are exported from China, because Chinese generic medicines are gaining increasing acceptance in developed economies such as the US and the EU.
Such a phenomenon is part of the larger picture that China is becoming a generic medicine powerhouse in the world, due to Chinese pharmaceutical firms' growing research and development capacity, he said.
The decrease in import value was mostly because of the decline in the average price of imported medical products, due to intensified competition among pharmaceutical companies caused by drug group buying trials, generic drug evaluations and other measures to increase medicine accessibility, despite the increase in imports.
Chinese pharmaceutical companies are strengthening their presence on the world stage with an increasing number of generic drug approvals from the United States, thanks to rising research and development capabilities and official support for innovation, industry insiders said.
According to statistics from the Healthcare Executive Institute, a leading healthcare industry think tank based in Beijing, as of Dec 24, 2018, Chinese pharmaceutical companies had received 77 generic drug approvals - known as abbreviated new drug applications or ANDAs - from the US Food and Drug Administration.
A recent example is a generic drug made by Qingdao Baheal Pharmaceutical Ltd, a holding subsidiary of Baheal Pharmaceutical Group headquartered in Beijing and Qingdao, Shandong province.
最近的一个例子是由北京和山东青岛的百汇医药集团旗下的子公司——青岛百汇海源药业有限公司生产的一款仿制药。
Its generic drug Nida, which is an extended-release tablet containing metformin, a medicine widely used to manage type-2 diabetes, was approved by the USFDA on Dec 27, 2018.
其生产的通用药物Nida，是一种包含广泛用于控制2型糖尿病药物——二甲双胍的缓释片剂，于2018年12月27日获得了美国食品药品监督管理局（USFDA）的批准。
Another reason is that once a generic drug receives US approval, it is automatically seen as having passed China's generic consistency evaluation requirements.
另一个原因是，一旦一种仿制药获得美国批准，它就会被视为自动通过了中国的仿制药一致性评价要求。
In 2016, the Chinese central authorities issued an opinion on "conducting consistency evaluations of the quality and efficacy of generic drugs", signaling a push for an industrywide overhaul of generic drug quality.
2016年，中国中央政府发布了关于“开展仿制药质量和疗效一致性评价”的意见，标志着对仿制药质量进行全面行业整改的推进。
Besides, if three titles of a generic drug have passed the evaluation, others will not be allowed for government tendering.
此外，如果一种仿制药已经拥有三个通过评估的品规，那么其他品规将不允许参与政府招标。